The take-private deal should give Premier more capital to bolster its operations and invest in technology.
Premier to go private in $2.6B deal with California investment firm Read More »
While last week’s recommended changes by CDC advisors to the MMRV vaccine schedule are unlikely to have a tangible effect on Merck’s business, the company said the removal of choice for healthcare providers is “concerning.”
As Kennedy Takes Aim at Childhood Vaccines, a History of Merck’s ProQuad Read More »
The government submitted a 49-page brief urging the high court to affirm Trump’s broad emergency levies.
White House asks Supreme Court to uphold Trump’s tariff powers Read More »
Recent changes to federal guidance for prescribing COVID-19 vaccinations have providers worried for what’s to come. “We have opened a door to not using science to guide care,” said one physician.
Vaccine access disparity between states roils patients, providers Read More »
Industry leaders should engage with state lawmakers on AI bills, given many legislators have limited experience in healthcare or AI, experts said at the HIMSS AI Leadership Strategy Summit.
States are ramping up AI regulation. How should healthcare respond? Read More »
An advisory committee last year found that Zynquista’s benefit-risk profile in type 1 diabetes was unfavorable due to cases of diabetic ketoacidosis.
After FDA Rejection, Lexicon’s Type 1 Diabetes Drug Hit With Another Regulatory Delay Read More »
The agency has also pointed to the use of Tylenol and other acetaminophen products during pregnancy as potentially linked to neurological and developmental defects in children, following a press conference Monday in which President Donald Trump did the same.
FDA Revives Decades-Dormant Drug as Potential Autism Treatment Read More »
In its rejection letter, the FDA flagged problems at a third-party fill-finish site owned by Novo Nordisk. Issues at this site have previously been investigated by the regulator.
Much Maligned Manufacturing Site Trips Up Scholar Rock’s Spinal Muscular Atrophy Drug Read More »
By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William Blair.
Ionis Heads to FDA As Antisense Therapy Aces Pivotal Study in Rare Neurological Disease Read More »
XRP es la moneda del proyecto Ripple y en el último año ha experimentado un crecimiento impresionante. Durante años, el precio de la moneda se mantuvo en un determinado nivel, y todo ello tenía que ver con la prolongada demanda judicial entre la SEC y XRP. Desde que el pr …
